Exelixis Inc (EXEL.O)

EXEL.O on Nasdaq

1.76USD
21 Nov 2014
Price Change (% chg)

$0.02 (+1.15%)
Prev Close
$1.74
Open
$1.78
Day's High
$1.78
Day's Low
$1.69
Volume
1,504,644
Avg. Vol
3,954,121
52-wk High
$8.41
52-wk Low
$1.35

EXEL.O

Chart for EXEL.O

About

Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is... (more)

Overall

Beta: 2.49
Market Cap (Mil.): $339.68
Shares Outstanding (Mil.): 195.22
Dividend: --
Yield (%): --

Financials

  EXEL.O Industry Sector
P/E (TTM): -- 269.72 39.20
EPS (TTM): -1.47 -- --
ROI: -81.80 -1.77 17.16
ROE: -757.78 -3.18 18.09
Search Stocks

UPDATE 1-Roche, GSK melanoma pill combinations look similar in showdown

* Shares in Roche's biotech partner Exelixis jump 20 pct (Adds Exelixis share price jump, more on treatment debate)

29 Sep 2014

BUZZ-Exelixis Inc: Positive skin cancer data

** Cancer drug developer's shares up 26 pct at $1.97 premarket

29 Sep 2014

US STOCKS-Wall St set for flat open; manufacturing data on tap

* Exelixis tumbles after cancer drug fails study; to cut jobs

02 Sep 2014

US STOCKS-Futures inch higher ahead of manufacturing data

* Exelixis tumbles after cancer drug fails study; to cut jobs

02 Sep 2014

Exelixis to cut jobs after prostate cancer drug fails late-stage study

- Cancer drug developer Exelixis Inc said on Monday it would cut about 70 percent of its workforce after its experimental prostate cancer drug cabozantinib failed a late-stage study.

01 Sep 2014

Exelixis to cut jobs after prostate cancer drug fails late-stage study

Sept 1 - Cancer drug developer Exelixis Inc said on Monday it would cut about 70 percent of its workforce after its experimental prostate cancer drug cabozantinib failed a late-stage study.

01 Sep 2014

Competitors

  Price Change
AstraZeneca plc (AZN.L) 4,741.00p +30.00
Pfizer Inc. (PFE.N) $30.45 +0.01
ArQule, Inc. (ARQL.OQ) $1.26 -0.02
GlaxoSmithKline plc (GSK.L) 1,481.50p +4.50
Algeta ASA (ALGETA.OL) -- --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: S&P Capital IQ Quantitative Report
$115.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks